Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AK 106 001616

Next Previous
Drug Profile

AK 106 001616

Alternative Names: AK-106; AK106-001616

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei
  • Class Analgesics; Anti-inflammatories; Antirheumatics
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Japan
  • 30 Jul 2015 Phase-II development for Rheumatoid arthritis is ongoing in Europe
  • 30 Jul 2015 NDR project - Asahi Kissei, AR 2014 (pipeline of May 2014) - pII (overseas) for RA - http://www.asahi-kasei.co.jp/asahi/en/ir/annual/14en.pdf; no latest pipeline

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top